Gilead says that the FDA has approved Descovy, as a pre-exposure prophylaxis to reduce the risk of acquiring HIV-1 infection from sex.
- FDA approves sNDA for Descovy under a priority review designation, becoming second drug to prevent HIV infection
- Efficacy of Descovy for PrEP were evaluated in randomized, double-blind multinational trial in 5,387 HIV-negative men and transgender women who have sex with men and were at risk of HIV-1 infection
- Trial showed that Descovy was similar to Truvada in reducing risk of acquiring HIV-1 infection
- Gilead CEO Daniel O’Day says Descovy matches Truvada’s “high efficacy with statistically significant improvements in ...